PTGS2 and neoplasm: The molecular endpoints used in our studies reflect those that are known to contribute both to initiating events (DNA adducts) and to co-carcinogenesis or tumor promoting events (GJIC and COX-2) and not meant as endpoints for complete carcinogenesis.